CLL Pharma-Product Pipeline Review-2015

CLL Pharma-Product Pipeline Review-2015

  • Products Id :- GMDHC06987CDB
  • |
  • Pages: 21
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

CLL Pharma-Product Pipeline Review-2015


Global Markets Direct's, 'CLL Pharma-Product Pipeline Review-2015', provides an overview of the CLL Pharma's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CLL Pharma's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of CLL Pharma including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of CLL Pharma's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the CLL Pharma's pipeline products

Reasons To Buy

Evaluate CLL Pharma's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of CLL Pharma in its therapy areas of focus

Identify new drug targets and therapeutic classes in the CLL Pharma's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of CLL Pharma and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of CLL Pharma

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of CLL Pharma and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

CLL Pharma Snapshot 4

CLL Pharma Overview 4

Key Information 4

Key Facts 4

CLL Pharma-Research and Development Overview 5

Key Therapeutic Areas 5

CLL Pharma-Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products-Monotherapy 8

CLL Pharma-Pipeline Products Glance 9

CLL Pharma-Clinical Stage Pipeline Products 9

Phase I Products/Combination Treatment Modalities 9

CLL Pharma-Early Stage Pipeline Products 10

Preclinical Products/Combination Treatment Modalities 10

Discovery Products/Combination Treatment Modalities 11

CLL Pharma-Drug Profiles 12

SYN-1002 12

Product Description 12

Mechanism of Action 12

R&D Progress 12

Syn-2001 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

Syn-2004 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

CLL Pharma-Pipeline Analysis 15

CLL Pharma-Pipeline Products by Target 15

CLL Pharma-Pipeline Products by Molecule Type 16

CLL Pharma-Pipeline Products by Mechanism of Action 17

CLL Pharma-Dormant Projects 18

CLL Pharma-Locations And Subsidiaries 19

Head Office 19

Appendix 20

Methodology 20

Coverage 20

Secondary Research 20

Primary Research 20

Expert Panel Validation 20

Contact Us 20

Disclaimer 21

List of Tables

CLL Pharma, Key Information 4

CLL Pharma, Key Facts 4

CLL Pharma-Pipeline by Indication, 2015 6

CLL Pharma-Pipeline by Stage of Development, 2015 7

CLL Pharma-Monotherapy Products in Pipeline, 2015 8

CLL Pharma-Phase I, 2015 9

CLL Pharma-Preclinical, 2015 10

CLL Pharma-Discovery, 2015 11

CLL Pharma-Pipeline by Target, 2015 15

CLL Pharma-Pipeline by Molecule Type, 2015 16

CLL Pharma-Pipeline Products by Mechanism of Action, 2015 17

CLL Pharma-Dormant Developmental Projects,2015 18

List of Figures

CLL Pharma-Pipeline by Top 10 Indication, 2015 6

CLL Pharma-Pipeline by Stage of Development, 2015 7

CLL Pharma-Monotherapy Products in Pipeline, 2015 8

CLL Pharma-Pipeline by Top 10 Target, 2015 15

CLL Pharma-Pipeline by Top 10 Molecule Type, 2015 16

CLL Pharma-Pipeline Products by Top 10 Mechanism of Action, 2015 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of CLL Pharma; CLL Pharma - Key Therapeutics; CLL Pharma - Pipeline Overview and Promising Molecules; CLL Pharma - News; CLL Pharma - Latest Updates; CLL Pharma - Pipeline; CLL Pharma - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107685
Site License
USD 3000 INR 215370
Corporate User License
USD 4500 INR 323055



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]